# Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)

> **NCT02304354** · PHASE3 · COMPLETED · sponsor: **University Hospital, Tours** · enrollment: 70 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02304354
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-09
- **Primary completion:** 2019-04-09
- **Final completion:** 2019-12-18
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02304354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02304354, "Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02304354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*